Navigation Links
Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
Date:6/8/2008

Presentation Details Statistically Significant and Clinically Relevant Results for SB-509 in Development for Treatment of Diabetic Neuropathy

SAN FRANCISCO, June 8 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of encouraging Phase 1b clinical data from its ZFP Therapeutic(TM) program at the 68th Scientific Sessions of the American Diabetes Association (ADA). As disclosed in an oral presentation entitled, "Evidence of Neuroregeneration Using Vascular Endothelial Growth Factor (VEGF) Zinc Finger Protein Activator (SB-509) in Diabetic Neuropathy: A Chronic Degenerative Polyneuropathy," results of Sangamo's Phase 1b clinical trial (SB-509-401) demonstrated statistically significant improvements in measurements of nerve health and function in subjects with diabetic neuropathy.

"We are excited by the clinically relevant magnitude of improvements that were observed in measurements of nerve health and function in subjects with mild to moderate diabetic neuropathy over the six month trial period after a single administration of SB-509," commented the presenter, Mark Kipnes, M.D., lead investigator on the Phase 1 trial and an endocrinologist at the Diabetes and Glandular Disease Clinic, San Antonio, Texas. "Analgesics and antidepressants designed to control pain symptoms are the only drugs currently approved to treat this condition. In contrast, SB-509 is designed to address the actual nerve damage. These data demonstrate that SB-509 may have a neuroprotective and a neuroregenerative effect."

The data presented at ADA were collected from subjects with mild to moderate diabetic peripheral neuropathy enrolled in Sangamo's Phase 1b study of SB-509 (SB-509-401). Subjects recei
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
2. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
3. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
4. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
5. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
6. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
7. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
8. Magellan Biosciences Companies to Feature Automated Products and New Tests for MRSA at the American Society for Microbiology Meeting, Booth 743
9. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
10. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
11. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Glenmark Pharmaceuticals S.A. (GPSA), ... India (GPL), announces the discovery and initiation of ... candidate, GBR 1302, a HER2xCD3 bispecific antibody. GBR ... Biologics Research Centre located in La Chaux-de-Fonds, ... on Glenmark,s innovative BEAT antibody technology platform which ...
(Date:8/19/2014)... BIRMINGHAM, Ala. , Aug. 19, 2014  The Alabama ... re-affirmed that patients can sue drug makers who mislead doctors ... cause harmful side‑effects.  The case is Weeks v. Wyeth, and ... drug makers in that same case last year. Heninger Garrison ... represent the patient in the case, Danny Weeks ...
(Date:8/19/2014)... -- Minimally Invasive Devices Inc. (MID), a ... that Mitsubishi Corporation has formally agreed to exclusively distribute ... Japan . MID anticipates that FloShield will ... in the second half of 2015. ... Storz GMBH & Co. (endoscopic instruments and devices) in ...
Breaking Medicine Technology:Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 2Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 4Minimally Invasive Devices and Mitsubishi Medical Japan Forge Exclusive Distribution Agreement 2
... achieve undetectable viral load in Phase,IIa trial within ... care, SAN FRANCISCO, Nov. 1 New ... protease inhibitor (PI) being,developed by Tibotec BVBA for ... Tibotec will present findings from three TMC435 studies,including ...
... Higher Sustained Virological Response Rates Recognized as Marker ... 1 A new,independently-conducted study being presented at ... the Study of Liver Diseases (AASLD) shows that,PEGASYS(R) ... response (SVR) rates for hepatitis C patients as,compared ...
Cached Medicine Technology:Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 2Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 3Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 4Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 5New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 2New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 3New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 4New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 5New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 6New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 7
(Date:8/20/2014)... 20, 2014 Inc. Magazine recently ... its 33rd annual Inc. 500|5000, an exclusive ranking ... represents the most comprehensive look at the most ... such as Yelp, Pandora, Timberland, Dell, Domino’s Pizza, ... early exposure as members of the Inc. 500|5000. ...
(Date:8/20/2014)... 2014 Building on growing success ... predicted stage iii and iv pressure ulcers with ... approached 90%. A company spokesperson commented that these ... or academic settings. The resulting capabilities can be ... hospital-acquired conditions to help providers avoid financial losses ...
(Date:8/20/2014)... 2014 Ticketability.com has Theresa ... fair prices. The well-known medium has been thrilling many ... touring in 19 cities, with tickets becoming available August ... will visit are Albany, Baltimore, Trenton, Erie, Buffalo, Philadelphia, ... Hills and San Diego. The medium’s fans can obtain ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Blaine ... the innovative RevitaDERM® Psoriasis Treatment to ... associated with psoriasis. This all-in-one product was created ... RevitaDERM® Psoriasis Treatment is powered by coal tar ... associated with this effective ingredient. , RevitaDERM® ...
(Date:8/20/2014)... The “Human Insulin Market by Product Type ... Human Insulin (Rapid Acting, Long Acting, Premixed)], by ... - Forecast to 2019” provides a detailed overview ... trends,and strategies impacting the global human insulin market ... revenue and share analysis. , Browse 110 market ...
Breaking Medicine News(10 mins):Health News:Etransmedia Makes Exclusive List for the Eighth Consecutive Year in Inc. Magazine 2Health News:Etransmedia Makes Exclusive List for the Eighth Consecutive Year in Inc. Magazine 3Health News:Jvion Achieves Benchmark Accuracy in Pressure Ulcer Prediction 2Health News:Theresa Caputo Tour Tickets for Sale at Ticketability.com Cause a Buying Frenzy Among Customers Over Their Offering of Deeply Discounted Seats 2Health News:RevitaDERM® Psoriasis Treatment Now Available At Over 7,600 CVS/pharmacies 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 4
... Georgia Center for Biotechnology and Genomic Medicine has been selected ... of children involved in a worldwide study of the causes ... in the mammoth study that will eventually follow 8,000 at-risk ... collecting blood every three months as they go. , ...
... Bulletin,Board: DSCI), a provider of advanced wound care products, ... its agency for investor relations and,corporate communications., "Derma ... in part to our,recent acquisition of the first aid ... our MEDIHONEY(TM) products, and the licensing of DSC127, a,novel ...
... is the,most significant advancement in surgical medicine in ... variety of academic and private hospitals around,the world, ... globally. Despite the fact that both StomaphyX(TM) and,EsophyX(TM) ... U.S. centers,have already been trained to perform these ...
... ATLANTA, December 17, 2007A new American Cancer Society report ... cancer cases and 7.6 million cancer deaths (about 20,000 ... comes from the first-ever Global Cancer Facts & Figures, ... of Facts & Figures publications. The report estimates that ...
... with a team at the University of California, San ... affects a childs risk of getting Kawasaki disease (KD), ... throughout the body. The genetic variation influences immune ... as the risk of developing coronary artery aneurysms ...
... activities that stretch youngsters, creativity and forge bonds with ... -- When you,re Christmas shopping for toys, ignore the ... healthy childhood development and reinforce personal relationships. , "It,s ... imagination, manipulation, and change. If a toy is static ...
Cached Medicine News:Health News:MCG selected as RNA laboratory for worldwide diabetes study 2Health News:Derma Sciences Inc Selects Allen & Caron for Investor Relations and Corporate Communications 2Health News:Derma Sciences Inc Selects Allen & Caron for Investor Relations and Corporate Communications 3Health News:EndoGastric Solutions Opens Three Training Centers to Keep Up with Demand from Surgeons Wanting to Learn StomaphyX(TM) Procedures 2Health News:EndoGastric Solutions Opens Three Training Centers to Keep Up with Demand from Surgeons Wanting to Learn StomaphyX(TM) Procedures 3Health News:EndoGastric Solutions Opens Three Training Centers to Keep Up with Demand from Surgeons Wanting to Learn StomaphyX(TM) Procedures 4Health News:New report estimates 12 million cancer deaths worldwide 2Health News:International research collaboration narrows focus on genetic cause of Kawasaki disease 2Health News:International research collaboration narrows focus on genetic cause of Kawasaki disease 3Health News:Picking the Right Toys Isn't Child's Play 2
Quantel Medical introduces the new Aviso A/B, a new generation high definition ultrasound system in a unique laptop or desktop PC workstation....
... is the result of years of research ... innovation and value, continues to bring you ... CT 200 is faster and easier to ... The CT 200 is the latest innovation ...
The Excel Series from DGH-KOI is an excellent choice for the ophthalmic surgeon performing cataract and other general ophthalmic procedures. With a broad range of blade options and our special Excel ...
New! Visually superior, micrometer handle, single foot plate, blade extends to 3.0 mm....
Medicine Products: